Life sciences companies need to re-evaluate their oncology program strategies to better manage the unique complexities of oncological drug development and marketing.

Success of the program will depend on targeting an optimal mix of diseases and treatments, clearly defining their target product profiles, while leveraging critical stakeholders and partners to aid discovery and spur innovation. Although personalized or precision medicine adds significant complexity to any oncology program strategy, managing this aspect will be absolutely critical to success.